Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;38(6):1202-1212.
doi: 10.1038/s41375-024-02252-4. Epub 2024 Apr 18.

Measurable residual disease (MRD)-testing in haematological and solid cancers

Junren Chen  1   2 , Robert Peter Gale  3 , Yu Hu  4   5 , Wen Yan  4   5 , Tiantian Wang  4   5 , Wei Zhang  4   5
Affiliations
Review

Measurable residual disease (MRD)-testing in haematological and solid cancers

Junren Chen et al. Leukemia. 2024 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

RPG is a consultant to Antengene Biotech LLC; Medical Director, FFF Enterprises Inc.; A speaker for Janssen Pharma and Hengrui Pharma; Board of Directors: Russian Foundation for Cancer Research Support and Scientific Advisory Board, StemRad Ltd.

Figures

Fig. 1
Fig. 1
Optimal design of a randomised controlled trial that tests the efficacy of MRD-guided therapy.
Fig. 2
Fig. 2. Conditions that need to be met for MRD state to be a perfect surrogate for relapse risk when running clinical trials to compare efficacy of protocols.
To be able to use MRD state as a surrogate for cumulative incidence of relapse (CIR) when comparing protocols in clinical trials, it is crucial that MRD-test results have the same implications for CIR and follow-up interventions (or lack thereof) regardless of which protocol (A versus B) is used prior to the MRD-test. More explanations are available in Supplementary Methods.
See this image and copyright information in PMC

References

    1. Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med. 1958;259:66–74. - PubMed
    1. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550–4. - PubMed
    1. Kakizuka A, Miller WH, Jr., Umesono K, Warrell RP, Jr., Frankel SR, Murty VV, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66:663–74. - PubMed
    1. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317. - PubMed
    1. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20:1925–30. - PubMed